The purpose of this study was to test the hypothesis that plasma levels of adiponectin can predict angiographic in-stent restenosis after coronary stenting. We prospectively examined adiponectin levels in 127 consecutive patients undergoing elective coronary stenting. Restenosis was defined as more than 50% stenosis at follow-up study by quantitative coronary angiography. There were no significant differences in the clinical characteristics or angiographical findings between the groups with restenosis and no restenosis. The levels of adiponectin did not differ between the restenosis group and the no restenosis group (5.7±2.8 vs 5.9±3.6 µg/mL, p=0.72). The plasma levels of adiponectin were not related with the late loss index after coronary stenting (r=0.01, p=0.89). The levels of adiponectin were significantly lower in men than in women (5.5±3.2 vs 8.8±3.7 µg/ mL, p<0.001), and negatively correlated with body mass index (r=-0.21, p=0.01). We analyzed adiponectin levels in male, female, obese, non-obese, diabetes, and non-diabetes patients, however, there were no significant differences between the restenosis group and no restenosis group. This study has demonstrated that the measurement of adiponectin could not predict angiographic restenosis after elective coronary stenting, whereas the plasma levels of adiponectin were associated with some coronary risk factors in patients with coronary artery disease. (Jpn Heart J 2002; 43: 85-91) 
morbidity and mortality from cardiovascular causes.
3) Current advanced knowledge has revealed that adipose tissue is not only a simple energy pool, but it also secretes metabolic hormones, enzymes, anti-fibrinolytic proteins, and inflammatory cytokines. 4, 5) Recently, a novel, adipose-specific secretary protein, adiponectin, was discovered in the blood stream. 6) Several in vitro studies indicated that adiponectin is a collagen-like plasma protein, which plays important roles in the inhibition of inflammatory response and in anti-atherogenic function. 7, 8) Indeed, the importance of adiponectin in patients with coronary artery disease (CAD) has been demonstrated. 9) At the site of coronary angioplasty, inflammatory response can induce a chain reaction that causes restenosis, 1, 2) therefore, adiponectin might be a promising predictor for restenosis. Thus, we tested the hypothesis that plasma levels of adiponectin may predict angiographic in-stent restenosis after elective coronary stenting.
METHODS
Study population: We prospectively studied 127 consecutive patients with documented myocardial ischemia who underwent coronary stenting within four weeks after diagnostic angiography at Juntendo University Hospital. Patients with acute coronary syndrome and without follow-up angiography were excluded. All subjects gave informed consent and the Juntendo University Ethical Committee approved the study. Angiographic methods: Cardiac catheterization and stenting were performed according to standard methods. After intracoronary injections of isosorbide dinitrate, angiograms were obtained in 2 or more views at baseline, after the procedure, and at 6 months. The technical aspects of the procedure, including the choice of stent and balloon, duration of inflation and pressure, were determined by the individual operators. Follow-up angiography was performed at 6 months after coronary stenting. We used a cardiac imaging system (Cardio 500, Kontron Instruments) for quantitative coronary angiography (QCA) analysis. A single technician without any knowledge of the study results performed the QCA analysis. The absolute values for the reference, minimal luminal diameter, and percent diameter stenosis were measured by QCA. Acute gain, late lumen loss, and late loss index were calculated using standard formulas. Restenosis was defined as more than 50% stenosis in a follow-up study. Blood sampling and measurement of adiponectin: Blood samples were obtained before coronary stenting and the plasma levels of adiponectin were measured by enzyme-linked immunosorbent assay.
10)
Assessment of insulin sensitivity: Homeostasis model assessment-insulin resistance (HOMA-IR), determined by the following formula was used to assess insu- lin sensitivity: fasting plasma glucose (mM) × fasting insulin (µU/mL)/22.5. 11, 12) It was reported that this parameter is highly correlated with insulin sensitivity during euglycemic clamping 11, 12) Statistical analysis: Statistical intergroup differences were analyzed by the chisquare test and Student's t test. The correlation between 2 parameters was determined by simple linear regression analysis. A p<0.05 was considered statistically significant.
RESULTS
The baseline clinical and angiographic characteristics in the no-restenosis and restenosis groups are shown in Table I and Table II . There were no significant differences in age, gender, coronary risk factors including hypertension, obesity, smoking history and diabetes, insulin sensitivity assessed by HOMA-IR, angiographical findings including the numbers of diseased vessels, target lesions, and the prevalence of complex lesions between the groups. Table III summarizes the comparison of adiponectin levels between the groups. Plasma levels of adiponectin did not differ between the restenosis and no restenosis groups (5.7±2.8 vs 5.9 ±3.6 µg/mL, p=0.72). Figure 1 presents the relationship between plasma adiponectin levels and late loss index. There was no correlation between the plasma levels of adiponectin and late loss index after coronary stenting (r=0.01, p=0.89). We also assessed the possibility of interactions between adiponectin levels and other clinical factors. Plasma levels of adiponectin were significantly lower in men than in women (5.5±3.2 vs 8.8±3.7 µg/mL, p<0.001), and negatively correlated with body mass index (BMI) (r=−0.21, p=0.01). There was no significant difference in the plasma levels of adiponectin between the diabetic and non-diabetic groups. Furthermore, there was no correlation between the plasma levels of adiponectin and HOMA-IR (r=−0.16, p=0.13). We further analyzed the levels of adiponectin in male, female, obese, non-obese, diabetic, and non-diabetes patients, however, there were no significant differences between the restenosis and no restenosis groups (Table III) . LAD=left anterior descending coronary artery; LCX=left circumflex coronary artery; RCA=right coronary artery. Complex lesions were defined as lesion types B2 and C according to the American College of Cardiology/ American Heart Association grading system. Coil stents were defined as GFX and Wiktor, and no coil stents were defined as Multi-Link, Palmaz-Schatz, and NIR. 
DISCUSSION
This study has demonstrated that plasma levels of adiponectin are associated with some coronary risk factors in patients with coronary artery disease, however, plasma levels of adiponectin could not predict angiographic restenosis after elective coronary stenting.
At the site of coronary stenting, arterial injury may induce inflammatory responses that accelerate the activation of monocytes/macrophages, and endothelial denudation plays an important part in the enhanced neointimal hyperplasia. 1, 2) Adiponectin modulates the functions of macrophages and the inflammatory response of endothelial cells. [7] [8] [9] Therefore, we speculated that part of the restenosis risk in CAD patients was associated with hypoadiponectinemia, which might accelerate to the process of in-stent restenosis consisting of insufficient suppression of the activation of monocytes/macrophages and endothelial cells. However, the present study was not able to reveal the existence of a positive association between adiponectin levels and the risk of in-stent restenosis after elective coronary stenting.
Previous studies showed that adiponectin levels are associated with gender, BMI, diabetes, and insulin resistance. 10, [13] [14] [15] In this study, the levels of adiponectin had a significant relationship with gender and BMI, but not diabetes or insulin sensitivity assessed by HOMA-IR. The levels of adiponectin in these subjects were relatively low (men: 5.5±3.2 µg/mL, women: 8.8±3.7 µg/mL) compared with the levels of adiponectin in the previous study in which the mean levels of adiponectin were 7.9 µg/mL in healthy men and 11.7 µg/mL in healthy women. 13) Thus, it is possible that most patients in the present study have hypoadiponectinemia. We speculate that the differences in the adiponectin levels between diabetic and non-diabetic patients were relatively small, and the relationship between adiponectin levels and HOMA-IR might not show a significant association.
The present study consisted of a small sample size. Further studies, including large sample sizes, are needed. However, we found no correlation between the plasma levels of adiponectin and late loss index in the group of elective coronary stenting patients, even though the findings were analyzed in terms of male, female, obese, non-obese, diabetes, and non-diabetes. Second, we only measured the baseline levels of adiponectin. We evaluated the BMI, which showed a significant positive correlation with adiponectin, before and after elective coronary stenting in these patients, however, there was no significant difference between the two phases.
Although the small sample size does not enable us to come to a definite conclusion, this is the first study to investigate the association between adiponectin and in-stent restenosis. The plasma levels of adiponectin could not predict angio-
